GT Biopharma, Inc.GTBPNASDAQ
Loading
R&D Expense Growth Under PressureDecelerating
Percentile Rank29
Year-over-Year Change
Year-over-year research & development expense growth
Latest
-40.12%
↓ 117% vs avg
Percentile
P29
Within normal range
Streak
1 yr
Consecutive declineDecelerating
Average
239.58%
Historical baseline
| Period | Value |
|---|---|
| 2025 | -40.12% |
| 2024 | -10.33% |
| 2023 | -26.61% |
| 2022 | -8.13% |
| 2021 | 1877.53% |
| 2020 | -70.91% |
| 2019 | -81.61% |
| 2018 | 748.97% |
| 2017 | 9.54% |
| 2016 | -2.50% |